

# *Inhibition of Activin/Myostatin signalling induces skeletal muscle hypertrophy but impairs mouse testicular development*

Article

Published Version

Creative Commons: Attribution 4.0 (CC-BY)

Open access

Vaughan, D., Ritvos, O., Mitchell, R., Kretz, O., Lalowski, M., Amthor, H., Chambers, D., Matsakas, A., Pasternack, A., Collins-Hooper, H., Ballesteros, R., Huber, T. B., Denecke, B., Widera, D. ORCID: <https://orcid.org/0000-0003-1686-130X>, Mukherjee, A. and Patel, K. (2020) Inhibition of Activin/Myostatin signalling induces skeletal muscle hypertrophy but impairs mouse testicular development. *European journal of translational myology*, 30 (1). pp. 62-78. ISSN 2037-7452 doi: 10.4081/ejtm.2019.8737 Available at <https://centaur.reading.ac.uk/88550/>

It is advisable to refer to the publisher's version if you intend to cite from the work. See [Guidance on citing](#).

To link to this article DOI: <http://dx.doi.org/10.4081/ejtm.2019.8737>

Publisher: PAGEPress

All outputs in CentAUR are protected by Intellectual Property Rights law, including copyright law. Copyright and IPR is retained by the creators or other copyright holders. Terms and conditions for use of this material are defined in

the [End User Agreement](#).

[www.reading.ac.uk/centaur](http://www.reading.ac.uk/centaur)

## **CentAUR**

Central Archive at the University of Reading

Reading's research outputs online

## Inhibition of Activin/Myostatin signalling induces skeletal muscle hypertrophy but impairs mouse testicular development

Danielle Vaughan (1), Olli Ritvos (2), Robert Mitchell (1), Oliver Kretz (3), Maciej Lalowski (4), Helge Amthor (5), David Chambers (6), Antonios Matsakas (7), Arja Pasternack (2), Henry Collins-Hooper (1), Randy Ballesteros (8), Tobias B. Huber (3), Bernd Denecke (9), Darius Widera (10), Abir Mukherjee (8), Ketan Patel (1)

(1) School of Biological Sciences, University of Reading, UK; (2) Department of Bacteriology and Immunology, University of Helsinki, Helsinki, Finland; (3) III Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; (4) Department of Biochemistry and Developmental Biology, HiLIFE, Meilahti Clinical Proteomics Core Facility, University of Helsinki, Helsinki, Finland; (5) Versailles Saint-Quentin-en-Yvelines University, INSERM U1179, LIA BAHN CSM, Montigny-le-Bretonneux 78180, France; (6) Functional Genomics, King's college, London, England; (7) Molecular Physiology Laboratory, Centre for Atherothrombosis & Metabolic Disease, Hull York Medical School, Hull, UK; (8) Royal Veterinary College, London, UK; (9) RWTH Aachen University, Aachen, Germany; (10) School of Pharmacy, University of Reading, UK

This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (CC BY-NC 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

### Abstract

Numerous approaches are being developed to promote post-natal muscle growth based on attenuating Myostatin/Activin signalling for clinical uses such as the treatment neuromuscular diseases, cancer cachexia and sarcopenia. However there have been concerns about the effects of inhibiting Activin on tissues other than skeletal muscle. We intraperitoneally injected mice with the Activin ligand trap, sActRIIB, in young, adult and a progeric mouse model. Treatment at any stage in the life of the mouse rapidly increased muscle mass. However at all stages of life the treatment decreased the weights of the testis. Not only were the testis smaller, but they contained fewer sperm compared to untreated mice. We found that the hypertrophic muscle phenotype was lost after the cessation of sActRIIB treatment but abnormal testis phenotype persisted. In summary, attenuation of Myostatin/Activin signalling inhibited testis development. Future use of molecules based on a similar mode of action to promote muscle growth should be carefully profiled for adverse side-effects on the testis. However the effectiveness of sActRIIB as a modulator of Activin function provides a possible therapeutic strategy to alleviate testicular seminoma development.

**Key Words:** Muscle hypertrophy, Activin, Myostatin, adverse effects, neuromuscular diseases, Mossman-Pacey paradox, testis.

*Eur J Transl Myol 30 (1): xx1-x17, 2020*

Skeletal muscle is an adaptable tissue capable of changing its mass and composition to meet the physiological needs of the human body.<sup>1</sup> The amount of protein present in any organ is controlled by the rate of its synthesis and breakdown and it has been estimated that, in humans, it has a turnover rate of 5.7g/kg/day,<sup>2</sup> with skeletal muscle proteins having an average half-life of only 20 days<sup>3</sup> Therefore, the regulation of skeletal muscle protein content is highly dynamic, and any failures in the mechanisms responsible may manifest in muscle loss or atrophy. A variety of clinically relevant

factors have been described that lead to muscle loss including genetic mutations (e.g. Duchenne Muscular Dystrophy-DMD), diseases in non-skeletal muscles that produce muscle wasting molecules (as in cancer cachexia) and age-related muscle wasting (sarcopenia). Given that muscle wasting is such a common feature of human life, it is hardly surprising that great efforts have been made to understand muscle loss with a view of attenuating or reversing this process. Many different molecules have received interest from a therapeutic perspective over the last few decades including anabolic

steroids,<sup>4</sup> growth hormones,<sup>5</sup> and IGF-1.<sup>6</sup> However all of these are associated with adverse side effects.

The landscape of muscle growth promoting molecules was revolutionised following the discovery of Myostatin.<sup>7</sup> In a ground-breaking study, the group of Se-Jin Lee showed that this member of the TGF- $\beta$  family of secreted signalling proteins was predominantly expressed by skeletal muscle during embryogenesis and its deletion in mouse (the *Mstn*<sup>-/-</sup> line) led to a huge increase in muscle mass as a consequence of muscle hyperplasia and fibre hypertrophy.<sup>7</sup> Thereafter mutations in the *Myostatin* (*Mstn*) gene have been found in a number of mammalian species including one case in humans all of which manifest with muscle hypertrophy.<sup>8</sup> Thereafter a number of strategies have been developed to attenuate the activity of Myostatin during post-natal life in-order to promote muscle growth for therapeutic uses. These include: antibodies and a variety of proteins (including Follistatin,<sup>9</sup> GASP-1,<sup>10</sup> LTBP-3<sup>11</sup>) that bind to Myostatin and prevent it from functioning normally, and propeptide regions that re-associate with Myostatin.<sup>12</sup> Alternative anti-Myostatin strategies have been developed based on ligand-receptor interactions. Myostatin and related TGF $\beta$  ligands such as Activin exert their action by binding to a heterotetrameric receptor complex comprised of two Type I and two Type II receptors on their target cells. Myostatin/Activin signalling is mediated by either ALK4 or ALK7 and ACVR2A or ACVR2B (henceforth ActRIIA or ActRIIB, respectively).<sup>13</sup> This knowledge has been exploited to develop ligand blocking antibodies to ActRIIB which have been shown to promote robust muscle hypertrophy.<sup>14</sup> In addition, we and others developed a stabilised peptide containing the ligand binding domain of ActRIIB (hereafter referred to as sActRIIB) which also promotes skeletal muscle growth.<sup>15</sup> The latter two strategies are particularly attractive in terms of muscle wasting therapies since it has been shown that Activin as well as Myostatin signal through the ActRIIB receptor to inhibit muscle growth; sActRIIB promotes muscle growth in the *Mstn*<sup>-/-</sup> mice.<sup>16</sup> However studies have shown the sActRIIB binds a number of forms of Activin as well as GDF11 and BMPs 2,7, 9 and 10.<sup>17-20</sup>

The broad ligand-binding spectrum of sActRIIB raises the concern that although it is able to promote muscle growth, it may interfere with other cellular processes. Indeed, the use of a sActRIIB molecule in primates was shown to increase pancreas and spleen weights as well as interfering with glucose homeostasis.<sup>21</sup>

In this study we examined the impact of sActRIIB on the development of the testis and sperm as both processes have been shown to be regulated by Activin. The mammalian testis is a complex organ composed of several cell types, organised in structurally distinct domains that undertake its two main functions. The seminiferous tubule is where spermatogenesis occurs and between these convoluted tubules are the interstitial cells, blood vessels and the sites of male hormone production.

Within the seminiferous tubule, surrounded by a basement membrane are Sertoli cells (SC). These are somatic cells that interact with the spermatogenic cells and act as support cells for spermatogenesis. SC proliferate and differentiate in the postnatal testis and the maximum number of SC per testis is established by day 15 in mice. Spermatogenesis is closely linked to SC function. At the basal surface of the seminiferous tubule between the SCs reside spermatogonial stem cells which gives rise to spermatogonia. Spermatogonia undergo a series of mitotic divisions that lead to spermatogonial renewal and differentiation into Type A and then Type B spermatogonia. These then undergo mitosis and differentiation to produce primary or preleptotene spermatocytes. Importantly, these diploid cells traverse through the blood-testis barrier (BTB), a tight junction between two adjacent SCs to reach the adluminal compartment. The BTB physically prevent the movement of molecules between the circulation and the adluminal compartment, isolating the adluminal compartment and sperm from the rest of the periphery. This transit is a prerequisite for the secondary or leptotene spermatocyte to enter meiotic division producing haploid round spermatids which undergo a series of differentiation steps to ultimately generate spermatozoa

TGF $\beta$  ligand signalling is a crucial regulator of spermatogenesis. Among these factors, Activin is known to play a role at least in early stages of postnatal testicular development in mice. Evidence supports a role of Activin in determining Sertoli cell numbers and spermatogonial maturation.<sup>22,23</sup> Activin expression in the testis peaks in postnatal week 1 and is diminished after the establishment of the full complement of SC numbers by the end of week 2.<sup>24</sup> A measurement of total Activin protein per testis however demonstrates a trough around day 20 and then increased expression from day 30 onwards. Moreover, *in-situ* hybridization data localises *InhBA* and *InhBB* transcripts in SC, spermatogonium as well as spermatocytes in the adult.<sup>24</sup> There is also evidence that Activin is produced in peritubular myoid cells.<sup>23</sup> These findings support a role for Activin in testicular function beyond SC number regulation in the early postnatal testis. Indeed, mice with a deletion of ActRIIA show a significant impairment of testicular growth and spermatogenesis underscoring the importance of TGF $\beta$  ligands that bind to this receptor in testicular development and function.<sup>8,25</sup>

Since the sActRIIB ligand-trap is known to bind Activin,<sup>26</sup> and that Activin action is crucial for testicular development and function we sought to investigate whether increase in muscle mass induced by sActRIIB is accompanied by changes in testicular biology. We have investigated whether there is a developmental window (age of mice) within which these effects are restricted and whether they are reversible over periods of non-intervention. Finally, to compare and contrast the testicular effect of inhibition of Activin or Myostatin we

**Table 1. Antibody details**

Primary antibodies Antigen	Species	Dilution	Supplier
PCNA	Mouse	1:200	Cell signalling Technology #25865
PLZF (D-9)	Mouse	1:250	Santa Cruz Biotechnology #sc-28319
Stra8	Rabbit	1:1000	Abcam ab49405
Sox9	Rabbit	1:1000	Abcam ab185966
AQP3	Rabbit	1:800	Abcam ab125219
Phospho-Smad2 (Ser465/467)/Smad3 (Ser423/425)	Rabbit	1:1000	Cell signalling Technology #8828
Smad2/Smad3	Rabbit	1:1000	Cell signalling Technology #3102
Phospho-AKT (Ser473)	Rabbit	1:1000	Cell signalling Technology #4060
AKT	Rabbit	1:1000	Cell signalling Technology #9272
Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204)	Rabbit	1:1000	Cell signalling Technology #9101
p44/42 MAPK (Erk1/2)	Rabbit	1:1000	Cell signalling Technology #4695
Alpha-tubulin	Mouse	1:1000	Cell signalling Technology #3873s
Secondary antibodies	Species	Dilution	Supplier
AlexaFluor 488 anti-mouse	Goat	1:200	Invitrogen
Rabbit anti mouse IgG HRP	Rabbit	1:200	DAKO #PO260
Goat anti-rabbit IgG HRP	Goat	1:5000	ThermoFisher scientific #65-6120

have also investigated the testicular phenotype of *Mstn* null mice. We show that sActRIIB treatment decreases testis size at any stage of the life of mice. Furthermore, we show that the testis phenotype persists longer than muscle hypertrophy following the withdrawal of sActRIIB treatment.

## Materials and Methods

### Ethical approval

The experiments were performed under a United Kingdom Home Office project licence, in agreement with the Animals (Scientific Procedures) Act 1986. The University of Reading Animal Care and Ethical Review Committee approved all procedures. Animals were humanely sacrificed via Schedule 1 killing.

### Animal maintenance

All mice used were bred and maintained in accordance to the Animals (Scientific Procedures) Act 1986 (UK) and approved by the Biological Resources Unit of University of Reading. Post-natal Myostatin/Activin block was induced via intraperitoneal (IP) injection with 10mg/kg of sActRIIB-Fc (hereafter sActRIIB) twice weekly. The age of initial injection varied among different studies. CD1 mice were obtained from Jackson laboratories and bred for pups. 10mg/kg sActRIIB-Fc was injected at P17 until P37 in all CD1 mice studies with three collection points; P37, P56 and P180. *Mstn*<sup>+/+</sup> and *Mstn*<sup>-/-</sup> tissues were obtained from Versailles Saint-Quentin-en-Yvelines University at 7.5 months of age. ERCC1  $\Delta$ -mice were bred as previously described (27) with

sActRIIB injections given from 7 weeks of age until 16 weeks.

### Histological analysis and immunohistochemistry

Following dissection, testes were weighed and fixed in 4% PFA prior to 4°C storage. PFA fixed testis were embedded in paraffin following a series of ethanol and histoclear stages. 8µm sections were cut using a Leica RM2155 rotary microtome prior to dewaxing in Xylene. Rehydration with ethanol stages was then performed prior to antigen retrieval in 0.01M citrate buffer pH6. Blocking buffer (10% FBS in TBS-Tx) was incubated on sections for 45 minutes at room temperature prior to incubation with primary antibody overnight at 4°C. Sections were subsequently washed in PBS-Tx three times prior to incubation with secondary antibody. Secondary antibodies attached to a fluorophore were used for detection of all antibodies except PLZF and PCNA which were detected using the Vectastain ABC-HRP kit with a Vector NOVAREd HRP substrate. All primary antibodies being detected were subsequently incubated with a secondary antibody for 1 hour at room temperature prior to detection. Details of primary and secondary antibodies are given in Table 1.

### Haematoxylin and eosin

Teste sections were dewaxed in xylene prior to rehydration in ethanol stages. Harris haematoxylin solution (Sigma HHS16) was then incubated on the slides for 2 minutes prior to acidic alcohol and tap water for blueing. Eosin solution (Sigma-Aldrich 318906) was

incubated on sections for 2 minutes prior to dehydration in ethanol and clearing with xylene. Slides were mounted with a coverslip and DPX mounting media.

## *TM4 Sertoli cell line analysis*

In 24 well plate dishes approximately 70,000 TM4 cells were seeded per well. Cells were allowed to attach to the bottom of the dish for approximately 12 hours in cultured media (DMEM/F12-Gibco 11330032- supplemented with 10% FBS and 100Units/mL Penicillin 100ug/mL Streptomycin). After the 12 hours, culture media was supplemented with either 10ng/mL Activin A, 10ng/mL GDF8 or 10ng/mL GDF11. After 1 hour of supplementation, cell nuclei were stained with Nuc-Blue Life cell dye (Invitrogen) and images acquired on a Leica inverted microscope with UV filter. After 24 hour of culture cells were fixed with 4% PFA pH7.4 stained with DAPI and imaged on a Leica upright microscope. Cells were counted using the particle analysis function incorporated on public domain image analyses software Fiji. TM4 cells similarly treated for 15min were collected to prepare protein lysates as described below.

## *Testis Protein Lysate Preparation and Western Blotting*

Frozen tissues were homogenised in detergent-free lysis buffer (50mM Tris pH 7.5, 150mM NaCl, 1mM Na<sub>3</sub>VO<sub>4</sub>, 1mM NaF, 1mM MgCl<sub>2</sub>) using a tissue grinder. These tissue lysates were then adjusted to 0.5% Triton X-100, 0.5% NP40 and incubated on ice for 15 minutes with intermittent mixing. TM4 cells were collected and directly lysed in lysis buffer as above but also containing 0.5% TritonX-100 and 0.5% NP40 and incubated on ice for 15 min with intermittent mixing. Lysates were clarified by centrifugation at 500g and protein content estimated by Bradford assay (Bio-Rad, Hercules, CA, USA). Protein western blotting was performed using standard techniques. Briefly, 100µg lysates were separated on 10% acrylamide gels and then transferred to nitrocellulose membranes (Amersham Biosciences, Piscataway, NJ, USA). Membranes were washed in TBST (50mM Tris pH7.5, 150mM NaCl, 0.05% Tween 20) and incubated with blocking buffer (5% non-fat dry milk in TBST) at room temperature for 1 hour. Protein blots were incubated with primary antibodies, used at 1:1000 in blocking buffer, overnight at 4°C. Membranes were then washed three times with TBST and incubated with appropriate horseradish peroxidase conjugated secondary antibodies (Sigma, St. Louis, MO, USA). The membranes were again washed four times and the immunoblot was visualized by ECL (Amersham Biosciences, Piscataway, NJ, USA). Immunoreactive protein bands were analysed using the public domain Image J program. Blots were stripped and reprobed with additional antibodies using standard methods. Briefly, stripping buffer (62.5mM Tris pH6.8, 2% SDS, 100mM β-mercaptoethanol) was pre-heated to 50°C in a water bath and membranes were placed into containers containing 100ml stripping buffer and left to

incubate at 50°C for 40 minutes with gentle shaking. After membranes were removed from stripping buffer, they were washed extensively in TBST. Membranes were subsequently blocked again in 5% milk block for 1 hour before additional primary antibodies were applied.


## *Statistical analysis*

Data are presented as mean  $\pm$  SE. Significant differences between two groups were performed by the Student's t-test for independent variables. Normal distribution of data was first determined. Thereafter one-way analysis of variance followed by Bonferroni's multiple comparison tests was used for statistical differences between groups of more than two. Statistical analysis was performed on GraphPad Prism 5 with statistically significant differences considered at  $P < 0.05$ .

## **Results**

### *Acute impact of attenuation of Activin Receptor IIB signalling on the development of skeletal muscle and the testis*

Inhibiting ligand binding to the Activin Receptor IIB has been demonstrated in a number of differing contexts to induce muscle growth in adult mice.<sup>27-29</sup> Here we examined the outcome of exposing very young mice. This is a period of development akin to the proposed optimum window for treating boys with DMD, to the soluble form of the Activin type IIB receptor (sActRIIB), which has been previously shown to prevent both Activin and Myostatin from binding to their receptor. Mice were injected twice weekly through the intraperitoneal route from p17 to p35 and culled at p37 (Fig. 1A). The body weights were not significantly changed by sActRIIB treatment (Fig. 1B). In contrast all the muscles examined had increased in weight, exemplified by the 20% increase in gastrocnemius mass (Fig. 1C). During the course of tissue recovery, we noticed that the testis were smaller in the sActRIIB treated group compared to those receiving vehicle (PBS) (Fig. 1D). The testis from the sActRIIB cohort were also smaller when their weight was expressed as a ratio to body weight (data not shown). We investigated the underlying cellular cause for the decreased testis weight through histological and immunocytochemical investigations. Individual seminiferous tubules were readily identifiable in both cohorts with expected peritubular, basal, adluminal cellular distribution and lumen. The tubule diameters from sActRIIB treated mice, however, were significantly smaller after sActRIIB treatment compared to controls (Fig. 1, E and H). Lumen area was smaller in sActRIIB treated samples than those of controls but did not reach statistical significance (Fig. 1F). Finally the area of the cellular component of each tubule was measured and revealed that this parameter was lower in sActRIIB treated samples compared to controls (Fig. 1G). These findings suggest a reduction of spermatogenesis upon sActRIIB treatment. We then sought to elucidate whether sActRIIB treatment led to alterations in cellular



**Fig 1.** *sActRIIB* causes a reduction in testicular development in young CD1 mice. (A) Schematic of experimental design. Black arrows injection of 10mg/kg *sActRIIB*. Red arrows indicate time of cull. (B) Body weight at P37. (C) Gastrocnemius mass. (D) Teste mass. (E) Average tubule area. (F) Average lumen area. (G) Average differentiation thickness. (H) H&E of seminiferous tubule in PBS & *sActRIIB* treated showing smaller tubule with *sActRIIB*. (I) PCNA positive cells in PBS & *sActRIIB* tubules showing a reduction in *sActRIIB* tubule. (J) PLZF positive cells in PBS & *sActRIIB* tubules. (K) Stra8 positive cells in PBS & *sActRIIB* tubules. (L) Sox9 positive cells in PBS & *sActRIIB* tubules. (M) Quantification of PCNA positive cells per tubule. (N) Quantification of PLZF positive cells per tubule. (O) Quantification of Stra8 positive cells per tubule. (P) Quantification of Sox9 positive cells per tubule. n=5 PBS treated male mice, n=6 *sActRIIB* treated male mice. Scale for all images represents 50 $\mu\text{m}$ . Student's t-Test used for statistical significance. \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ . H&E, haematoxylin & eosin; PCNA, proliferating cell nuclear antigen; PLZF, promyelocytic leukemia zinc finger; Stra8, Stimulated By Retinoic Acid 8; Sox9, SRY-Box 9.


distribution or processes in the testis that might cause a likely reduction in spermatogenesis.

*sActRIIB* treatment decreases proliferation of cells in the testis of young mice

To assess whether the reduction of seminiferous tubule cross section is caused by reduced cell proliferation we

quantified the number of proliferating cell nuclear antigen (PCNA) expressing cells. While the location of proliferating cells, adjacent to the basement membrane did not differ, there were significantly fewer proliferating cells in the tubules of *sActRIIB* treated samples than controls (Fig. 1, I and M). Since proliferating cells, A and B type spermatogonial cells, within tubules originate






**Fig 2.** *sActRIIB* causes a reduction in testes weight and tubule areas at P56 in CD1 mice. (A) Schematic of experimental design. Black arrows show injection of 10mg/kg *sActRIIB*. Red arrows indicate time of cull. (B) Body weight at P56. (C) Gastrocnemius mass. (D) Teste mass. (E) Average tubule area. (F) Average lumen area. (G) Average differentiation thickness. (H) H&E of seminiferous tubule in PBS & *sActRIIB* treated showing smaller tubule with *sActRIIB*. (I) PCNA positive cells in PBS & *sActRIIB* tubules showing a reduction in *sActRIIB* tubule. (J) PLZF positive cells in PBS & *sActRIIB* tubules. (K) *Stra8* positive cells in PBS & *sActRIIB* tubules. (L) *Sox9* positive cells in PBS & *sActRIIB* tubules. (M) AQP3 positive tubules. (N) Quantification of PCNA positive cells per tubule. (O) Quantification of PLZF positive cells per tubule. (P) Quantification of *Stra8* positive cells per tubule. (Q) Quantification of *Sox9* positive cells per tubule. (R) Quantification of AQP3 positive tubules as a percentage of total tubules.  $n=5$  PBS treated male mice,  $n=5$  *sActRIIB* treated male mice. Scale for all images represents 50μm. Student's *t*-Test used for statistical significance. \* $p<0.05$ , \*\* $p<0.01$ , \*\*\* $p<0.001$ . H&E, haematoxylin & eosin; PCNA, proliferating cell nuclear antigen; PLZF, promyelocytic leukemia zinc finger; *Stra8*, Stimulated By Retinoic Acid 8; *Sox9*, SRY-Box 9.

from spermatogonial stem cells (SSC) we quantified the SSC population using PLZF immunostaining,<sup>30</sup> and found that *sActRIIB* treatment did not affect spermatogonial stem cell number per tubule (Fig. 1, J and N) or the ability of preleptotene spermatocyte to enter meiosis as demonstrated in Fig. 1, K and O by *Stra8* staining.<sup>31</sup> Lastly we quantified the number of Sertoli cells, identified by *Sox9* expression,<sup>32</sup> which supports and thus ultimately limits the extent of spermatogenesis

in each tubule and found no differences in this parameter between the *sActRIIB* treated group and controls (Fig. 1, L and P). Importantly, at this time point we did not see evidence of sperm tails either through H - E staining or immunostaining with sperm tail specific markers,<sup>33</sup> including Aquaporin3 (Fig. 1H and data not shown). Of note, there was no effect on Leydig cell numbers by *sActRIIB* treatment (data not shown).






**Fig 3.** *sActRIIB* causes a reduction in testes weight and tubule areas at P56 in C57/B10 mice. (A) Schematic of experimental design. Black arrows injection of 10mg/kg *sActRIIB*. Red arrows indicate time of cull. (B) Body weight at P56. (C) Gastrocnemius mass. (D) Teste mass. (E) Average tubule area. (F) Average lumen area. (G) Average differentiation thickness. (H) H&E of seminiferous tubule in PBS & *sActRIIB* treated showing smaller tubule with *sActRIIB*. (I) PCNA positive cells in PBS & *sActRIIB* tubules showing a reduction in *sActRIIB* tubule. (J) PLZF positive cells in PBS & *sActRIIB* tubules. (K) Stra8 positive cells in PBS & *sActRIIB* tubules. (L) Sox9 positive cells in PBS & *sActRIIB* tubules. (M) AQP3 positive tubules. (N) Quantification of PCNA positive cells per tubule. (O) Quantification of PLZF positive cells per tubule. (P) Quantification of Stra8 positive cells per tubule. (Q) Quantification of Sox9 positive cells per tubule. (R) Quantification of AQP3 positive tubules as a percentage of total tubules.  $n=5$  PBS treated male mice,  $n=5$  *sActRIIB* treated male mice. Scale for all images represents 50 $\mu$ m. Student's t-Test used for statistical significance. \* $p<0.05$ , \*\* $p<0.01$ , \*\*\* $p<0.001$ . H&E, haematoxylin & eosin; PCNA, proliferating cell nuclear antigen; PLZF, promyelocytic leukaemia zinc finger; Stra8, Stimulated By Retinoic Acid 8; Sox9, SRY-Box 9.

### *sActRIIB* decreases sperm number

The data from examining the testis of p37 mice demonstrated that *sActRIIB*, while promoting muscle growth, prevented them from developing to their normal size. While testicular cell proliferation was reduced in mice treated with *sActRIIB* in the prepubertal stage, we wanted to investigate whether this affects sperm production in the adult. To that end we carried out the same experiment as outlined in Figure 1 except that mice were culled at p56 (adult) since sperm are not fully

matured in mice at p37. Examination of body weights of mice treated from p17 to p35 and left for another 21 days (to p56) showed that the *sActRIIB* treated groups were heavier (23%) than those injected with PBS (Fig. 2, A and B). Although the gastrocnemius muscle in the *sActRIIB* group had increased in weight (by 56%), the testes were lighter (by 19%) than those of controls (Fig. 2, C and D). Similar to the P37 mice, the cross-section of the seminiferous tubules from treated mice were smaller which was quantitatively verified to show a decrease in



**Fig 4.** sActRIIB causes a reduction in tubule areas at P180. (A) Schematic of experimental design. Black arrows indicate injection of 10mg/kg sActRIIB. Red arrows indicate time of cull. (B) Body weight at P180. (C) Gastrocnemius mass. (D) Testis mass. (E) Average tubule area. (F) Average lumen area. (G) Average differentiation thickness. (H) H&E of seminiferous tubule in PBS & sActRIIB treated showing smaller tubule with sActRIIB. (I) PCNA positive cells in PBS & sActRIIB tubules showing a reduction in sActRIIB tubule. (J) PLZF positive cells in PBS & sActRIIB tubules. (K) Stra8 positive cells in PBS & sActRIIB tubules. (L) Sox9 positive cells in PBS & sActRIIB tubules. (M) AQP3 positive tubules. (N) Quantification of PCNA positive cells per tubule. (O) Quantification of PLZF positive cells per tubule. (P) Quantification of Stra8 positive cells per tubule. (Q) Quantification of Sox9 positive cells per tubule. (R) Quantification of AQP3 positive tubules as a percentage of total tubules. n=5 PBS treated male mice, n=5 sActRIIB treated male mice. Scale for all images represents 50μm. Student's t-Test used for statistical significance. \*p<0.05, \*\*p<0.01, \*\*\*p<0.001. H&E, haematoxylin & eosin; PCNA, proliferating cell nuclear antigen; PLZF, promyelocytic leukemia zinc finger; Stra8, Stimulated γ Retinoic Acid 8; Sox9, SRY-Box 9.

tubule area, lumen area and thickness of spermatogenic area in sActRIIB treated samples (Fig. 2, E-H). Again, like the p37 experiment, the number of proliferating cells was decreased in sActRIIB samples (Fig. 2, I and N) but there was no change in the density of PLZF, Stra8 and Sox9 positive cells (Fig. 2, I-L and O-Q). By p57, however, the control cohort contained matured spermatozoa, as evidenced by tails marked by aquaporin

3, in the seminiferous tubule lumen which was very significantly reduced in sActRIIB treated samples (Fig. 2, M and R).

We examined whether genetic background was a modifying factor in terms of tissue response to exposure to sActRIIB. We carried out a series of experiments using C57B110 (Fig. 3) as well as the FVB (data not shown) background. In both strains, injection of sActRIIB at p17


to p35 followed by tissue isolation at p56 (Fig. 3A) resulted in robust muscle mass increase (Fig. 3B) and a decrease in testis weight (Fig. 3C). Again there was a decrease in tubule area, lumen area as well as differentiation area (Fig. 3D-F). As for the CD1 background, immunocytochemical studies revealed a decrease in the number of PCNA and AQP3 containing tubules without any significant changes in PLZF, Stra8 or Sox9 levels (Fig. 3G-Q).

Therefore, treatment of young mice with sActRIIB results in sustained increased skeletal muscle levels but smaller testis which (at least for the CD1 strain)

contained less than the normal number of mature spermatozoa.

#### *sActRIIB treatment in young mice results in long term testicular abnormalities*

We then investigated whether the reduced spermatogenesis in adult mice caused by a cellular proliferation defect resulting from sActRIIB treatment of pre-pubertal mice, was of a permanent nature or whether this effect was reversible. To that end we injected mice until p35 and examined tissues at p180 (Fig. 4, A-R). Here we failed to detect any significant difference in




**Fig. 5** *sActRIIB* causes a reduction in testes weight and tubule areas when administered in fully developed adult mice. (A) Schematic of experimental design. Black arrows indicate injection of 10mg/kg *sActRIIB*. Red arrows indicate time of cull. (B) Body weight at P112. (C) Gastrocnemius mass. (D) Teste mass. (E) Average tubule area. (F) Average lumen area. (G) Average differentiation thickness. (H) H&E of seminiferous tubule in PBS & *sActRIIB* treated showing smaller tubule with *sActRIIB*. (I) PCNA positive cells in PBS & *sActRIIB* tubules showing a reduction in *sActRIIB* tubule. (J) PLZF positive cells in PBS & *sActRIIB* tubules. (K) Stra8 positive cells in PBS & *sActRIIB* tubules. (L) Sox9 positive cells in PBS & *sActRIIB* tubules. (M) AQP3 positive tubules. (N) Quantification of PCNA positive cells per tubule. (O) Quantification of PLZF positive cells per tubule. (P) Quantification of Stra8 positive cells per tubule. (Q) Quantification of Sox9 positive cells per tubule. (R) Quantification of AQP3 positive tubules as a percentage of total tubules. n=4 PBS treated male mice, n=4 *sActRIIB* treated male mice. Scale for all images represents 50μm. Student's t-Test used for statistical significance. \*p<0.05, \*\*p<0.01, \*\*\*p<0.001. H&E, haematoxylin & eosin; PCNA, proliferating cell nuclear antigen; PLZF, promyelocytic leukemia zinc finger; Stra8, Stimulated By Retinoic Acid 8; Sox9, SRY-Box 9; AQP3, Aquaporin 3.



body, muscle or testis weight between the two cohorts. However examination of testis still showed that the sActRIIB cohort displayed lower tubule area and differentiation area compared to the PBS treated mice.

Additionally the sActRIIB cohort contained fewer spermatozoa as quantified through AQP3 staining analyses (Fig. 4, M and R).




**Fig 6.** sActRIIB causes a reduction in testes weight and tubule areas in *Ercc1* $\Delta$ / $\Delta$  treated mice. (A) Schematic of experimental design. Black arrows injection of 10mg/kg sActRIIB. Red arrows indicate time of cull. (B) Body weight at P112. (C) Gastrocnemius mass. (D) Teste mass. (E) Average tubule area. (F) Average lumen area. (G) Average differentiation thickness. (H) H&E of seminiferous tubule in PBS & sActRIIB treated showing smaller tubule with sActRIIB. (I) PCNA positive cells in PBS & sActRIIB tubules showing a reduction in sActRIIB tubule. (J) PLZF positive cells in PBS & sActRIIB tubules. (K) Stra8 positive cells in PBS & sActRIIB tubules. (L) Sox9 positive cells in PBS & sActRIIB tubules. (M) AQP3 positive tubules. (N) Quantification of PCNA positive cells per tubule. (O) Quantification of PLZF positive cells per tubule. (P) Quantification of Stra8 positive cells per tubule. (Q) Quantification of Sox9 positive cells per tubule. (R) Quantification of AQP3 positive tubules as a percentage of total tubules.  $n=4$  PBS treated male mice,  $n=4$  PBS treated *Ercc1* $\Delta$ / $\Delta$  male mice,  $n=5$  sActRIIB treated *Ercc1* $\Delta$ / $\Delta$  male mice. Scale for all images represents 50 $\mu$ m. One-way ANOVA followed by Bonferroni's multiple comparison tests, \* $p<0.05$ , \*\* $p<0.01$ , \*\*\* $p<0.001$ . H&E, haematoxylin & eosin; PCNA, proliferating cell nuclear antigen; PLZF, promyelocytic leukemia zinc finger; Stra8, Stimulated By Retinoic Acid 8; Sox9, SRY-Box 9; AQP3, Aquaporin 3.

*sActRIIB induces testis atrophy in adult mice and in model of aged mice*

The experiments conducted thus far were initiated in young mice. We next determined the consequence of sActRIIB treatment on adult mice as well as in a model of extreme ageing. In the first set of these experiments, adult mice (p56) were treated until p110 and thereafter culled at p112 (Fig. 5, A-R). sActRIIB treated mice showed a non-significant increase in body weight but a significant increase in muscle weight compared to

controls (Fig. 5, B-C). In contrast, the testis were lighter in the sActRIIB group compared to controls (Fig. 5, D). The sActRIIB group showed non-significant decrease in tubule area, lumen area as well as differentiation area (Fig. 5, E-G). Nevertheless PCNA counts were lower in the sActRIIB group (Fig. 5, N) as were the number of tubules containing AQP3 positive spermatozoa (Fig. 5, R).


Thereafter we examined the consequence of sActRIIB treatment on the *ErccΔ/-* mice, an established mouse model of ageing.<sup>34</sup> Mice were injected from p56 (before



**Fig. 7.** Testes weight and tubule areas are reduced in *Mstn* heterozygous and *Mstn* null mice. (A) Body weight at 7.5 months. (B) Teste mass. (C) Average tubule area. (D) Average lumen area. (E) Average differentiation thickness. (F) H&E of seminiferous tubule in PBS & sActRIIB treated showing smaller tubule with sActRIIB. (G) PCNA positive cells in PBS & sActRIIB tubules showing a reduction in sActRIIB tubule. (H) PLZF positive cells in PBS & sActRIIB tubules. (I) Stra8 positive cells in PBS & sActRIIB tubules. (J) Sox9 positive cells in PBS & sActRIIB tubules. (K) AQP3 positive tubules. (L) Quantification of PCNA positive cells per tubule. (M) Quantification of PLZF positive cells per tubule. (N) Quantification of Stra8 positive cells per tubule. (O) Quantification of Sox9 positive cells per tubule. (P) Quantification of AQP3 positive tubules as a percentage of total tubules.  $n=4$  PBS treated male mice,  $n=5$  *Mstn*<sup>+/-</sup> male mice,  $n=4$  *Mstn*<sup>-/-</sup> male mice. Scale for all images represents 50μm. One-way ANOVA followed by Bonferroni's multiple comparison tests, \* $p<0.05$ , \*\* $p<0.01$ , \*\*\* $p<0.001$ . H&E, haematoxylin & eosin; PCNA, proliferating cell nuclear antigen; PLZF, promyelocytic leukemia zinc finger; Stra8, Stimulated By Retinoic Acid 8; Sox9, SRY-Box 9

signs of overt ageing) and tissues collected at p112 a time point which we have previous shown to be equivalent of over 2.5 mouse years (Fig. 6A).<sup>27</sup> Progeric mice displayed lower body weights compared to controls at p112 (Fig. 6B). sActRIIB treatment of progeric mice resulted in a non-significant increase in body weight (Fig. 6B) accompanied by an increase in muscle mass albeit not reaching control levels (Fig. 6C). In contrast, testis weights were lowered in *ErccΔ/-* mice by sActRIIB (Fig. 6D). Tubule area, lumen area as well as differentiation thickness was smaller in *ErccΔ/-* testis compared to controls which reduced further following the treatment of *ErccΔ/-* mice with sActRIIB (Fig. 6, E-G). Immunocytochemical analysis revealed crucial interplay

between progeric mechanisms and inhibition of TGFβ signalling in the *ErccΔ/-* mice. Whereas levels of proliferating cells, number of cells undergoing meiosis and mature spermatozoa were lower in the *ErccΔ/-* tissue compared to controls, there was no difference between these cohorts in terms of the number of primary germ cells or Sertoli cells (Fig. 6, H-R). Treatment of *ErccΔ/-* mice with sActRIIB resulted in a significant decrease in PCNA and AQP3 containing tubules and a non-significant reduction in Sertoli cell number. Most interestingly, sActRIIB treatment lead to almost a complete downregulation of AQP3 in *ErccΔ/-* testes resulting in a total elimination of the sperm production.



**Fig 8.** Differential effects of TGFβ ligands on TM4 Sertoli cell proliferation and signalling. (A) Fold increase in the number of cells over 24h. (B) Immunoblot analyses of TM4 lysates that were either untreated or treated with 10ng/ml of indicated ligands for 15min for either phosphorylated or total target proteins (AKT, Smad2/3 and ERK) as indicated. (C) Bar graphs representing densitometric quantification of phosphorylated target protein normalised to total target protein from western blotting experiments shown in (B). Student's t-Test used for statistical significance. *n* = 3, \*\**p* < 0.01.



These experiments show that when prepubertal mice are treated with sActRIIB, there is a strong reduction of cellular proliferation which leads to reduced spermatogenesis later in life. This treatment however does not affect the resident spermatogonial stem cell population or their ability to enter meiosis. Further, this effect is not permanent and there is a modest recovery leading to sperm production later in life. Moreover, sActRIIB treatment at any stage in the life of a mouse is likely to decrease testis size and spermatogenesis. Crucially we have also identified an interaction between TGF $\beta$  signalling and ageing of the testis in that sActRIIB treatment synergises with progeroid signalling to prevent germ cell entry into meiosis

## *sActRIIB induces testicular side-effects in Myostatin null mice*

Our work shows that attenuation of signalling through the ActRIIB can lead to decreased testis mass. One of the molecules that promotes muscle mass through this receptor is Myostatin. To our knowledge a testicular phenotype has not been reported in Myostatin null mice but as a consequence of the results of this study, we examined both the heterozygous and null Myostatin variants. We found that both the heterozygous and homozygous Myostatin mutants had lower testis weights compared to WT litter mates (Fig. 7, A-B). The testis from the nulls were lighter than those from heterozygous mice but failed to reach statistical significance. Histological examination of the tissue revealed that both the heterozygous and null mice had decreased tubule, lumen and differentiation areas compared to WT litter mates (Fig. 7, C-F). Immunocytochemical studies revealed a decrease in the number of AQP3 containing tubules without any significant changes in PCNA, PLZF, Stra8 or Sox9 levels (Fig. 7, G-P).

Postnatal Sertoli cell numbers are regulated by FSH, IGF, testosterone, and Activin action. Since sActRIIB can inhibit Activin, Myostatin and GDF11 action, we addressed whether these ligands affect cellular proliferation in a Sertoli cell line, TM4. As shown in Fig. 8, A, only Activin induces TM4 cellular proliferation and not Mstn or GDF11. Importantly, when investigating proximal signalling effects of these three ligands on TM4 we found only Activin to significantly induce both Smad2 and AKT activation (Fig. 8, B and C). The lack of any effect of sActRIIB treatment on Sertoli cell numbers *in vivo* might be due to the fact that the injection regime started at p17, and Sertoli cell proliferation is known to occur up to p15 in mice.<sup>36</sup> Since Myostatin does not induce Smad2 phosphorylation in TM4 cells (Fig. 8, B and C), yet show a similar phenotype as that of mice treated with sActRIIB and since sActRIIB might not traverse the blood testis barrier, it is likely that the constellation of testicular defects described in this study might be due to the reduced effect of Activin and Myostatin action on cells of the spermatogonial lineage. Crucially, however Activin inhibition appears to affect

cells up to the primary spermatocytes, whereas the effect of Myostatin deletion is seen only in later stages.

## Discussion

ACE-031, a molecule similar to the sActRIIB used in this study, was progressed into a phase II clinical trial on boys with DMD. However the study was stopped due to safety concerns related to epitaxis and telangiectasias.<sup>37</sup> Previous work has reported that a similar molecule to ACE-031 and sActRIIB used in our study induced side effects related to the spleen and pancreas.<sup>21</sup> In this study we hypothesised that testis development may be affected by sActRIIB given the important role that Activin has on this organ. Our study shows that sActRIIB promotes robust muscle growth in a matter of 20 days in mice. However this was accompanied by a decrease in testis weight. This effect was independent to the genetic background of mice, since here we examined three routinely used strains (CD-1, C57/B10 and FVB). Examination of testicular structure showed that sActRIIB inhibited the proliferation of cells in testis without impacting on the number of germ cells, undergoing meiosis or Sertoli cells. We show that following cessation of sActRIIB treatment, the rate of muscle growth in treated mice is reduced compared to untreated mice such that by 145 days after last treatment both the treated and untreated mice have the same muscle mass (Figure 4). Importantly, although the muscle phenotype induced by sActRIIB treatment has been erased at this time, the testis phenotype has not. These results show that positive outcomes of sActRIIB treatment are shorter lived than that detrimental impact on the testis.

Importantly, we show that both mature wild-type mice and an ageing model undergo muscle hypertrophy and testicular atrophy following sActRIIB treatment. The most pronounced impact of the treatment in terms of potential testicular function was in fact in the model of aged mice where sActRIIB totally eliminated the formation of AQP3 positive sperm. We believe that the side effects detected after the application of sActRIIB at any stage of life is highly relevant since therapies based on attenuating Myostatin/Activin function are being developed for juvenile (e.g. DMD)<sup>38,39</sup> adult (heart failure)<sup>39</sup>, and late onset diseases, e.g. inclusion body myostis, oculopharyngeal muscular dystrophy,<sup>40,41</sup> as well as sarcopenic obesity.<sup>42</sup>

The data from our study regarding the inhibition of testis development can be explained by on-target effects that should be expected for a molecule that inhibits Activin.<sup>45</sup> It is surprising that, to the best of our knowledge, a testis phenotype has not been described in other studies using similar molecules which bring about muscle growth. In many studies there is no mention that the testis were examined and even when they were, there is not data presented regarding their mass.<sup>46-47</sup> It is also not clear whether testicular size was examined in boys on the ACE-083 trial. However, we suggest that in future this metric be included in any clinical trial that relies on

Myostatin/Activin neutralisation as the mode of action to promote muscle growth.

Although both sActRIIB treatment of wild-type mice and Myostatin deletion shows a reduction of spermatogenesis in mice, the mechanism of pathogenesis is likely to be different. Although Activin is known to play crucial local roles in both the pituitary and the ovary, sActRIIB treatment does not affect the ovarian cycle in mice (not shown) suggesting that the working of the hypothalamus-pituitary-gonad (HPG) axis is intact even in the presence of a circulating inhibitor of Activin. Given this, therefore, it is not expected that sActRIIB treatment affects pituitary function in the male. Contrasting the ovary, however, testicular function of spermatogenesis is strongly affected by sActRIIB most likely due to the abrogation of Activin action on the spermatogenic cells themselves. Removal of sActRIIB treatment restores spermatogenesis supporting a partially reversible nature of this brake on the process. This reversibility is expected since sActRIIB treatment does not affect SC or germ cell numbers. Contrasting from the *Mstn*<sup>-/-</sup> mouse testis, however, there is a clear reduction of PCNA positive cells close to the basement membrane inside the seminiferous tubule upon sActRIIB treatment. This is indicative of reduction of spermatogonial proliferation which then suggests that the reduction of testicular size and function in the injected model is due to early inhibition of spermatogenesis. The effectiveness of sActRIIB as a modulator of Activin function, demonstrated by the reduction of Smad2 activation, provides a possible therapeutic strategy to alleviate testicular seminoma development. It has been shown that when gonocyte differentiation to spermatogonia is compromised, the gonocytes produce cancer *in-situ* or CIS cells within the testis.<sup>45</sup> These cells develop into seminoma or non-seminoma origin cancers. Importantly, at every stage of the differentiation of the gonocyte to testicular cancer Smad2/3 activation appears to be a common factor. This activation might be effectively contained or inhibited by sActRIIB treatment.

In addition to effects on the testis, it is likely that the ligand trap might affect Activin action elsewhere in the body in a context-dependent manner. While angiogenesis, liver and kidney function might also be affected, a pronounced behavioural effect is also expected upon sActRIIB injection. There is clear evidence of ActRIIB expression in the amygdala indicating that Activin might play a role in anxiety-type behaviour. Moreover, it is known that the presence of Activin has a calming effect on the afferents from the amygdala whereas absence or reduction of Activin can lead to aggressive behaviour stemming from heightened anxiety. In support of this, we have found that sActRIIB treated male mice show highly aggressive behaviour (not shown). Our sActRIIB injection protocol, therefore, presents a model system to further investigate behavioural issues such as anxiety and anxiety-related aggression.

Our study details an experimental intervention in mice that leads to the development of muscularity but at the same time induces testicular atrophy. A similar outcome has been described in men who abuse androgenic anabolic steroids.<sup>53,54</sup> The co-presentation of these two traits in an organism are in conflict when viewed from evolutionary fitness perspective as big muscles in men are deemed indicative of high genetic quality and positive factors in mate selection by women.<sup>55</sup> This scenario is called the Mossman-Pacey Paradox which can be succinctly summarised as representing a conflict between masculinity and muscularity.<sup>56</sup> It is important to recognise that muscle mass increase induced through abuse of androgenic anabolic steroid is also associated with a list of other undesirable health issues including acne, gynaecomastia and most importantly mortality.<sup>53</sup> Future work will investigate these features in our mouse model of muscle growth induced by sActRIIB. Most importantly the work presented here should be taken as a warning sign for those who want to use Myostatin/Activin inhibitors for vanity purposes.

In summary, we demonstrate that attenuation of Myostatin/Activin signalling delivers significant muscle growth at any stage in the life of a rodent. However, sActRIIB injection induced an abnormal testis phenotype at any stage of the rodents life. The functional consequence of the decrease testis size may impact on fertility. Future work will investigate fertility of mice that have been treated with sActRIIB. Furthermore we will investigate in an appropriately timed manner the role this molecule plays on female reproductive organs.

## List of acronyms

ACE-031 - Acceleron 031 protein  
 ActRIIA - Activin receptor IIA  
 ActRIIB - Activin receptor IIB  
 ACVR2A - Activin receptor 2A  
 ACVR2B - Activin receptor 2B  
 ALK4 - Activin like kinase4  
 ALK7 - Activin like kinase7  
 AQP3 - Aquaporin 3  
 BMPs - Bone morphogenetic protein  
 BTB - blood-testis barrier  
 DMD - Duchenne Muscular Dystrophy  
 ECL - Enhanced chemiluminescence  
 GASP-1 - Growth and differentiation factor associated serum protein1  
 GDF11 - Growth and differentiation factor 11  
 IGF-1 - Insuline growth factor 1  
*InhBA* - Inhibin BA  
*InhBB* - Inhibin BB  
 IP - intraperitoneal  
 LTBP-3 - Latent TGF binding protein 3  
*Mstn* - Myostatin  
*Mstn*<sup>-/-</sup> - *Myostatin* null mice  
 PCNA - Proliferating cell nuscler antigen  
 PLZF - Promyelocytic Leukemia Zinc Finger  
 sActRIIB - soluble ActRIIB

SC - Sertoli cells  
 Smad2 - SMA Mothers Against Decapentaplegic 2  
 Sox9 - SRY Box transcription factor 9  
 Stra8 - Stimulated By Retinoic Acid 8  
 TGFβ - Transforming Growth Factor beta

## Authors contributions

Conceptualization OR, AM, KP. Methodology OK, AM, TBH, KP. Validation DV, ML, HM, RB, BD, DW, AM, KP. Formal Analysis DV, ML, HM, RB, BD, DW, AM, KP. Investigation DV, OR, RM, ML, HM, CD, AM, AP, HC-H, RB. Writing DV, ML, BD, DW, AM KP. Visualization DV, ML, BD, DW, AM, KP. Supervision AM, KP.

## Acknowledgments

Authors are grateful for the Editorial Office of European Journal of Translational Myology guidance during the publication of this paper.

## Funding

This work was supported by the Biotechnology and Biological Sciences Research Council (Grants BB/J016454/1 to HCH and KP and BB/M014878/1 to DV). TBH was supported by the DFG (CRC 1192, CRC1140, CRC 992), by the BMBF (01GM1518C), by the European Research Council-ERC (grant 616891) and by the H2020-IMI2 consortium BEAt-DKD (Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115974).

## Conflict of Interest

The authors have no conflicts to disclose.

## Ethical Publication Statement

We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.

## Corresponding Author

Ketan Patel, Hopkins Building, University of Reading, Reading, RG6 6UB – Phone: +44118 378 8079  
 Email: [ketan.patel@reading.ac.uk](mailto:ketan.patel@reading.ac.uk)

## E-mails of co-authors

Danielle Vaughan: [D.Vaughan@pgr.reading.ac.uk](mailto:D.Vaughan@pgr.reading.ac.uk)  
 Olli Ritvos: [olli.ritvos@gmail.com](mailto:olli.ritvos@gmail.com)  
 Robert Mitchell: [robmitchell1@gmail.com](mailto:robmitchell1@gmail.com)  
 Oliver Kretz: [o.kretz@uke.de](mailto:o.kretz@uke.de)  
 Maciej Lalowski: [maciej.lalowski@helsinki.fi](mailto:maciej.lalowski@helsinki.fi)  
 Helge Amthor: [helge.amthor@handimedex.onmicrosoft.com](mailto:helge.amthor@handimedex.onmicrosoft.com)  
 David Chambers: [david.2.chambers@kcl.ac.uk](mailto:david.2.chambers@kcl.ac.uk)  
 Antonios Matsakas: [Antonios.Matsakas@hymns.ac.uk](mailto:Antonios.Matsakas@hymns.ac.uk)  
 Arja Pasternack: [arja.pasternack@helsinki.fi](mailto:arja.pasternack@helsinki.fi)  
 Henry Collins-Hooper: [Henry.Collins-Hooper@uk.lockton.com](mailto:Henry.Collins-Hooper@uk.lockton.com)  
 Randy Ballesteros: [rballesteros@rvc.ac.uk](mailto:rballesteros@rvc.ac.uk)  
 Tobias B. Huber: [t.huber@uke.de](mailto:t.huber@uke.de)

Bernd Denecke: [Bernd.Denecke@rwth-aachen.de](mailto:Bernd.Denecke@rwth-aachen.de)  
 Darius Widera: [d.widera@reading.ac.uk](mailto:d.widera@reading.ac.uk)  
 Abir Mukherjee: [amukherjee@rvc.ac.uk](mailto:amukherjee@rvc.ac.uk)

## References

1. Matsakas A, Patel K. Skeletal muscle fibre plasticity in response to selected environmental and physiological stimuli. *Histol Histopathol* 2009;24:611-29.
2. Waterlow JC, Jackson AA. Nutrition and protein turnover in man. *Br Med Bull* 1981;37:5-10.
3. Poortmans JR, Carpentier A, Pereira-Lancha LO, Lancha A, Jr. Protein turnover, amino acid requirements and recommendations for athletes and active populations. *Braz J Med Biol Res* 2012;45:875-90.
4. Sjoqvist F, Garle M, Rane A. Use of doping agents, particularly anabolic steroids, in sports and society. *Lancet* 2008;371(9627):1872-82.
5. Windisch PA, Papatheofanis FJ, Matuszewski KA. Recombinant human growth hormone for AIDS-associated wasting. *Ann Pharmacother* 1998;32:437-45.
6. Borst SE, Lowenthal DT. Role of IGF-I in muscular atrophy of aging. *Endocrine* 1997;7:61-3.
7. McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. *Nature* 1997;387(6628):83-90.
8. Aiello D, Patel K, Lasagna E. The myostatin gene: an overview of mechanisms of action and its relevance to livestock animals. *Anim Genet* 2018;49:505-19.
9. Lee SJ, McPherron AC. Regulation of myostatin activity and muscle growth. *Proc Natl Acad Sci U S A* 2001;98:9306-11.
10. Hill JJ, Qiu Y, Hewick RM, Wolfman NM. Regulation of myostatin in vivo by growth and differentiation factor-associated serum protein-1: a novel protein with protease inhibitor and follistatin domains. *Mol Endocrinol* 2003;17:1144-54.
11. Anderson SB, Goldberg AL, Whitman M. Identification of a novel pool of extracellular pro-myostatin in skeletal muscle. *J Biol Chem* 2008;283:7027-35.
12. Matsakas A, Foster K, Otto A, et al. Molecular, cellular and physiological investigation of myostatin propeptide-mediated muscle growth in adult mice. *Neuromuscul Disord* 2009;19:489-99.
13. Olsen OE, Wader KF, Hella H, et al. Activin A inhibits BMP-signaling by binding ACVR2A and ACVR2B. *Cell Commun Signal* 2015;13:27.
14. Lach-Trifilieff E, Minetti GC, Sheppard K, et al. An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy. *Mol Cell Biol* 2014;34:606-18.
15. Hoogaars WM, Mouiel E, Pasternack A, et al. Combined effect of AAV-U7-induced dystrophin

- exon skipping and soluble activin Type IIB receptor in mdx mice. *Hum Gene Ther* 2012;23:1269-79.
16. Lee SJ, Reed LA, Davies MV, et al. Regulation of muscle growth by multiple ligands signaling through activin type II receptors. *Proc Natl Acad Sci U S A* 2005;102:18117-22.
  17. Sartori R, Schirwis E, Blaauw B, et al. BMP signaling controls muscle mass. *Nat Genet* 2013;45:1309-18.
  18. Cohen S, Nathan JA, Goldberg AL. Muscle wasting in disease: molecular mechanisms and promising therapies. *Nat Rev Drug Discov* 2015;14:58-74.
  19. Koncarevic A, Kajimura S, Cornwall-Brady M, et al. A novel therapeutic approach to treating obesity through modulation of TGFbeta signaling. *Endocrinology* 2012;153:3133-46.
  20. Liu H, Zhang R, Chen D, et al. Functional redundancy of type II BMP receptor and type IIB activin receptor in BMP2-induced osteoblast differentiation. *J Cell Physiol* 2012;227:952-63.
  21. Latres E, Mastaitis J, Fury W, et al. Activin A more prominently regulates muscle mass in primates than does GDF8. *Nat Commun* 2017;8:15153.
  22. Boitani C, Stefanini M, Fragale A, Morena AR. Activin stimulates Sertoli cell proliferation in a defined period of rat testis development. *Endocrinology* 1995;136:5438-44.
  23. Buzzard JJ, Farnworth PG, De Kretser DM, et al. Proliferative phase sertoli cells display a developmentally regulated response to activin in vitro. *Endocrinology* 2003;144:474-83.
  24. Buzzard JJ, Loveland KL, O'Bryan MK, et al. Changes in circulating and testicular levels of inhibin A and B and activin A during postnatal development in the rat. *Endocrinology* 2004;145:3532-41.
  25. Kumar TR, Varani S, Wreford NG, et al. Male reproductive phenotypes in double mutant mice lacking both FSHbeta and activin receptor IIA. *Endocrinology* 2001;142:3512-8.
  26. del Re E, Sidis Y, Fabrizio DA, et al. Reconstitution and analysis of soluble inhibin and activin receptor complexes in a cell-free system. *J Biol Chem* 2004;279:53126-35.
  27. Alyodawi K, Vermeij WP, Omaid S, et al. Compression of morbidity in a progeroid mouse model through the attenuation of myostatin/activin signalling. *J Cachexia Sarcopenia Muscle* 2019. 10:662-686. doi: 10.1002/jcsm.12404. Epub 2019 Mar 27.
  28. Relizani K, Mouisel E, Giannesini B, et al. Blockade of ActRIIB signaling triggers muscle fatigability and metabolic myopathy. *Mol Ther*. 2014;22:1423-33.
  29. Omaid S, Matsakas A, Degens H, et al. Enhanced exercise and regenerative capacity in a mouse model that violates size constraints of oxidative muscle fibres. *Elife* 2016;5. pii: e16940. doi: 10.7554/eLife.16940.
  30. Costoya JA, Hobbs RM, Barna M, et al. Essential role of Plzf in maintenance of spermatogonial stem cells. *Nat Genet* 2004;36(6):653-9.
  31. Zhou Q, Nie R, Li Y, et al. Expression of stimulated by retinoic acid gene 8 (Stra8) in spermatogenic cells induced by retinoic acid: an in vivo study in vitamin A-sufficient postnatal murine testes. *Biol Reprod* 2008;79:35-42.
  32. Morais da Silva S, Hacker A, Harley V, et al. Sox9 expression during gonadal development implies a conserved role for the gene in testis differentiation in mammals and birds. *Nat Genet* 1996;14:62-8.
  33. Chen Q, Peng H, Lei L, et al. Aquaporin3 is a sperm water channel essential for postcopulatory sperm osmoadaptation and migration. *Cell Res* 2011;21:922-33.
  34. Vermeij WP, Dolle ME, Reiling E, et al. Restricted diet delays accelerated ageing and genomic stress in DNA-repair-deficient mice. *Nature* 2016;537(7620):427-31.
  35. Oldknow KJ, Seebacher J, Goswami T, et al. Follistatin-like 3 (FSTL3) mediated silencing of transforming growth factor beta (TGFbeta) signaling is essential for testicular aging and regulating testis size. *Endocrinology* 2013;154:1310-20.
  36. Auharek SA, de Franca LR. Postnatal testis development, Sertoli cell proliferation and number of different spermatogonial types in C57BL/6J mice made transiently hypo- and hyperthyroidic during the neonatal period. *J Anat* 2010;216:577-88.
  37. Campbell C, McMillan HJ, Mah JK, et al. Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial. *Muscle Nerve*. 2017;55:458-64.
  38. Shieh PB. Emerging Strategies in the Treatment of Duchenne Muscular Dystrophy. *Neurotherapeutics* 2018;15:840-8.
  39. Roh JD, Hobson R, Chaudhari V, et al. Activin type II receptor signaling in cardiac aging and heart failure. *Sci Transl Med* 2019;11(482).
  40. Ioannis M, Foivos P, Dimitrios K. A review on the treatment of sporadic inclusion body myositis with Bimagrumab and Alemtuzumab. *Int J Neurosci* 2019;129:297-302.
  41. Harish P, Malerba A, Lu-Nguyen N, et al. Inhibition of myostatin improves muscle atrophy in oculopharyngeal muscular dystrophy (OPMD). *J Cachexia Sarcopenia Muscle* 2019;10:1016-26. doi: 10.1002/jcsm.12438. Epub 2019 May 7.
  42. Consitt LA, Clark BC. The Vicious Cycle of Myostatin Signaling in Sarcopenic Obesity: Myostatin Role in Skeletal Muscle Growth, Insulin

Signaling and Implications for Clinical Trials. *J Frailty Aging* 2018;7:21-7.

43. Tillet E, Bailly S. Emerging roles of BMP9 and BMP10 in hereditary hemorrhagic telangiectasia. *Front Genet* 2014;5:456.
44. Glasser CE, Gartner MR, Wilson D, et al. Locally acting ACE-083 increases muscle volume in healthy volunteers. *Muscle Nerve* 2018;57:921-6.
45. Dias V, Meachem S, Rajpert-De Meyts E, et al. Activin receptor subunits in normal and dysfunctional adult human testis. *Hum Reprod* 2008;23:412-20.
46. Morvan F, Rondeau JM, Zou C, et al. Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy. *Proc Natl Acad Sci U S A* 2017;114:12448-53.
47. Rooks D, Praestgaard J, Hariry S, et al. Treatment of Sarcopenia with Bimagrumab: Results from a Phase II, Randomized, Controlled, Proof-of-Concept Study. *J Am Geriatr Soc* 2017;65:1988-95.
48. Garito T, Roubenoff R, Hompesch M, et al. Bimagrumab improves body composition and insulin sensitivity in insulin-resistant individuals. *Diabetes Obes Metab* 2018;20:94-102.
49. Rodino-Klapac LR, Haidet AM, et al. Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease. *Muscle Nerve* 2009;39:283-96.
50. Johnston H, Baker PJ, Abel M, et al. Regulation of Sertoli cell number and activity by follicle-stimulating hormone and androgen during postnatal development in the mouse. *Endocrinology* 2004;145:318-29.
51. Mithraprabhu S, Mendis S, Meachem SJ, et al. Activin bioactivity affects germ cell differentiation in the postnatal mouse testis in vivo. *Biol Reprod* 2010;82:980-90.
52. Istasse L, Van Eenaeme C, Evrard P, et al. Animal performance, plasma hormones and metabolites in Holstein and Belgian Blue growing-fattening bulls. *J Anim Sci* 1990;68:2666-73.
53. Horwitz H, Andersen JT, Dalhoff KP. Health consequences of androgenic anabolic steroid use. *J Intern Med* 2019;285:333-40.
54. Knuth UA, Maniera H, Nieschlag E. Anabolic steroids and semen parameters in bodybuilders. *Fertil Steril* 1989;52:1041-7.
55. Sell A, Lukazsweski AW, Townsley M. Cues of upper body strength account for most of the variance in men's bodily attractiveness. *Proc Biol Sci* 2017;284(1869).
56. Mossman JA, Pacey AA. The fertility fitness paradox of anabolic-androgenic steroid abuse in men. *J Intern Med* 2019;286:231-2. doi: 10.1111/joim.12884. Epub 2019 Apr 10.

Submission: December, 05, 2019

Acceptance: December, 05, 2019